Nonavalent human papillomavirus vaccine - Beijing Health Guard Biotechnology
Alternative Names: HPV vaccine - Beijing Health Guard Biotechnology; Nonavalent HPV vaccine - Beijing Health Guard Biotechnology; Recombinant nonavalent (types 6/11/16/18/31/33/45/52/58) HPV vaccine - Beijing Health Guard BiotechnologyLatest Information Update: 19 Feb 2024
Price :
$50 *
At a glance
- Originator Beijing Health Guard Biotechnology
- Class Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Human papillomavirus infections
Most Recent Events
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in China for Human papillomavirus infections in males in 2027 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in Indonesia for Human papillomavirus infections (Prevention) in 2025 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)
- 08 Feb 2024 Beijing Health Guard Biotechnology plans to submit BLA in China for Human papillomavirus infections (Prevention) in females in 2025 (Parenteral) (Beijing Health Guard Biotechnology pipeline, February 2024)